Baidu
map

一图读懂:癫痫的发作类型及诱因

2015-10-22 美图 医学美图



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=154398, encodeId=d6d115439873, content=很形象明了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 08 21:07:33 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76497, encodeId=4665e649795, content=很好,可以入门, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160307/IMG56DD346053F0D5538.jpg, createdBy=7bed1697174, createdName=那夏花开, createdTime=Fri Apr 08 22:24:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41034, encodeId=2338410346d, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Sun Oct 25 12:50:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40864, encodeId=5c5240864b4, content=不错,很喜欢这个平台, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Sun Oct 25 09:05:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40643, encodeId=b5404064375, content=感谢感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29881651723, createdName=1ddcbc02m31(暂无匿称), createdTime=Sat Oct 24 15:58:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40368, encodeId=c8f14036801, content=谢谢小编,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Fri Oct 23 08:29:00 CST 2015, time=2015-10-23, status=1, ipAttribution=)]
    2016-11-08 1e1263e3m20(暂无匿称)

    很形象明了,学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=154398, encodeId=d6d115439873, content=很形象明了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 08 21:07:33 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76497, encodeId=4665e649795, content=很好,可以入门, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160307/IMG56DD346053F0D5538.jpg, createdBy=7bed1697174, createdName=那夏花开, createdTime=Fri Apr 08 22:24:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41034, encodeId=2338410346d, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Sun Oct 25 12:50:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40864, encodeId=5c5240864b4, content=不错,很喜欢这个平台, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Sun Oct 25 09:05:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40643, encodeId=b5404064375, content=感谢感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29881651723, createdName=1ddcbc02m31(暂无匿称), createdTime=Sat Oct 24 15:58:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40368, encodeId=c8f14036801, content=谢谢小编,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Fri Oct 23 08:29:00 CST 2015, time=2015-10-23, status=1, ipAttribution=)]
    2016-04-08 那夏花开

    很好,可以入门

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=154398, encodeId=d6d115439873, content=很形象明了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 08 21:07:33 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76497, encodeId=4665e649795, content=很好,可以入门, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160307/IMG56DD346053F0D5538.jpg, createdBy=7bed1697174, createdName=那夏花开, createdTime=Fri Apr 08 22:24:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41034, encodeId=2338410346d, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Sun Oct 25 12:50:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40864, encodeId=5c5240864b4, content=不错,很喜欢这个平台, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Sun Oct 25 09:05:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40643, encodeId=b5404064375, content=感谢感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29881651723, createdName=1ddcbc02m31(暂无匿称), createdTime=Sat Oct 24 15:58:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40368, encodeId=c8f14036801, content=谢谢小编,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Fri Oct 23 08:29:00 CST 2015, time=2015-10-23, status=1, ipAttribution=)]
    2015-10-25 slicer

    好东西

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=154398, encodeId=d6d115439873, content=很形象明了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 08 21:07:33 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76497, encodeId=4665e649795, content=很好,可以入门, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160307/IMG56DD346053F0D5538.jpg, createdBy=7bed1697174, createdName=那夏花开, createdTime=Fri Apr 08 22:24:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41034, encodeId=2338410346d, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Sun Oct 25 12:50:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40864, encodeId=5c5240864b4, content=不错,很喜欢这个平台, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Sun Oct 25 09:05:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40643, encodeId=b5404064375, content=感谢感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29881651723, createdName=1ddcbc02m31(暂无匿称), createdTime=Sat Oct 24 15:58:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40368, encodeId=c8f14036801, content=谢谢小编,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Fri Oct 23 08:29:00 CST 2015, time=2015-10-23, status=1, ipAttribution=)]
    2015-10-25 nizongzan

    不错,很喜欢这个平台

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=154398, encodeId=d6d115439873, content=很形象明了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 08 21:07:33 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76497, encodeId=4665e649795, content=很好,可以入门, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160307/IMG56DD346053F0D5538.jpg, createdBy=7bed1697174, createdName=那夏花开, createdTime=Fri Apr 08 22:24:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41034, encodeId=2338410346d, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Sun Oct 25 12:50:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40864, encodeId=5c5240864b4, content=不错,很喜欢这个平台, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Sun Oct 25 09:05:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40643, encodeId=b5404064375, content=感谢感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29881651723, createdName=1ddcbc02m31(暂无匿称), createdTime=Sat Oct 24 15:58:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40368, encodeId=c8f14036801, content=谢谢小编,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Fri Oct 23 08:29:00 CST 2015, time=2015-10-23, status=1, ipAttribution=)]
    2015-10-24 1ddcbc02m31(暂无匿称)

    感谢感谢!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=154398, encodeId=d6d115439873, content=很形象明了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 08 21:07:33 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76497, encodeId=4665e649795, content=很好,可以入门, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160307/IMG56DD346053F0D5538.jpg, createdBy=7bed1697174, createdName=那夏花开, createdTime=Fri Apr 08 22:24:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41034, encodeId=2338410346d, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Sun Oct 25 12:50:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40864, encodeId=5c5240864b4, content=不错,很喜欢这个平台, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Sun Oct 25 09:05:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40643, encodeId=b5404064375, content=感谢感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29881651723, createdName=1ddcbc02m31(暂无匿称), createdTime=Sat Oct 24 15:58:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40368, encodeId=c8f14036801, content=谢谢小编,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/29/bf4f15fc3880b83286648eb0481da33b.jpg, createdBy=0d741615323, createdName=pharmxing, createdTime=Fri Oct 23 08:29:00 CST 2015, time=2015-10-23, status=1, ipAttribution=)]
    2015-10-23 pharmxing

    谢谢小编,学习了

    0

相关资讯

抗癫痫药Aptiom单药治疗部分发作性癫痫在美国被批准上市

日本住友制药(Sunovion)近日宣布,FDA已批准Aptiom(醋酸艾司利卡西平)的补充新药申请(sNDA),将Aptiom作为一种单药疗法,用于部分发作性癫痫患者的治疗。此次批准,将使Aptiom可作为一种单药,用于首次接受治疗的患者以及从其他抗癫痫药物(AEDs)转向Aptiom的患者。之前,Aptiom已于2013年获FDA批准,作为一种辅助药物,用于部分发作性癫痫的治疗。截至目前,Ap

APA 2015:没事多听听音乐,有助于预防癫痫发作

Science Daily:没事多听听音乐,有助于预防癫痫发作据美国心理学会第123届年会的一项研究表明,癫痫患者的大脑与正常人的大脑对音乐的反应不同,这一发现可能会为预防癫痫的发作带来新的治疗方法。“我们相信,音乐可用于癫痫患者的干预治疗,”Christine Charyton说道。约80%的癫痫病例为颞叶癫痫,癫痫主要出现在大脑的颞叶。而处理音乐的听觉皮层恰位于颞叶,这就可以解释为何Chary

23岁女孩发生卒中,这改变了其生活方向

大学生Ishley Elmore正在进行教学实习时,她的一个学生注意到她的脸不动。Elmore说,她看了看老师,老师告诉她去看医生。Elmore唯一想到的是她父亲任教的那个学校的一个护士。因此,Elmore就开车去看护士。当她到达的时候,她的脸完全无知觉,并且失语了。23岁的Elmore还不知道自己发生了卒中。拯救生命的治疗:在医院,医生在确定Elmore的左侧大脑内形成了斑块后,应用tPA进行溶

Neurology:他汀类药物可降低卒中后癫痫发作风险

本研究评估了他汀类药物治疗卒中后癫痫发作的风险。 在这项单中心、队列研究中,收纳了初发缺血性脑卒中并且无癫痫中风史的患者。经过2.5年的平均随访,评估并确定卒中后癫痫发作的风险。通过逻辑回归和Cox回归分析评估了他丁药物与脑卒中后早发性癫痫发作(ES)和脑卒中后癫痫(PSE)之间的关系。利用美国国立卫生研究院脑卒中量表(NIHSS)评估脑卒中严重程度:轻度(<7分)、中度(7~25分)、重度(>

一个头,两个脑

1939年,十位年龄介于10岁到43岁的一群患有癫痫的人,前往了罗切斯特大学医学中心,而他们会在那里进行一项激进的新手术。 这些病人会来到这里的原因,是他们全都因为患有又猛烈又无法控制的癫痫发作而挣扎着。他们即将接受的手术,从来没在人类上测试过,但他们已经走投无路了——所有治疗癫痫发作的标准药物疗法都无效。 1939年的二月到五月之间,他们的外科医生,罗

Lancet:女性癫痫患者妊娠期间有风险!

女性癫痫患者的产前保健是多种多样的。癫痫和抗癫痫药物暴露与妊娠结局的关联需要量化指导管理。研究人员做了一项系统回顾和荟萃分析研究了癫痫和妊娠结果、有或没有接触抗癫痫药物之间的关联。研究人员在1990年1月1日和2015年1月21日之间检索了MEDLINE,EMBASE,Cochrane,AMED和CINAHL,没有任何语言或区域限制,对癫痫孕妇患者进行了观察性研究,以评估在产科并发症在产前,产时或

Baidu
map
Baidu
map
Baidu
map